1. Protein O-GlcNAcylation in cardiovascular diseases
- Author
-
Hui-fang Wang, Yi-xuan Wang, Yu-ping Zhou, Yun-peng Wei, Yi Yan, Ze-jian Zhang, and Zhi-cheng Jing
- Subjects
Pharmacology ,Cardiovascular Diseases ,Humans ,Heart ,Pharmacology (medical) ,General Medicine ,N-Acetylglucosaminyltransferases ,Protein Processing, Post-Translational ,beta-N-Acetylhexosaminidases ,Mitochondria - Abstract
O-GlcNAcylation is a post-translational modification of protein in response to genetic variations or environmental factors, which is controlled by two highly conserved enzymes, i.e. O-GlcNAc transferase (OGT) and protein O-GlcNAcase (OGA). Protein O-GlcNAcylation mainly occurs in the cytoplasm, nucleus, and mitochondrion, and it is ubiquitously implicated in the development of cardiovascular disease (CVD). Alterations of O-GlcNAcylation could cause massive metabolic imbalance and affect cardiovascular function, but the role of O-GlcNAcylation in CVD remains controversial. That is, acutely increased O-GlcNAcylation is an adaptive heart response, which temporarily protects cardiac function. While it is harmful to cardiomyocytes if O-GlcNAcylation levels remain high in chronic conditions or in the long run. The underlying mechanisms include regulation of transcription, energy metabolism, and other signal transduction reactions induced by O-GlcNAcylation. In this review, we will focus on the interactions between protein O-GlcNAcylation and CVD, and discuss the potential molecular mechanisms that may be able to pave a new avenue for the treatment of cardiovascular events.
- Published
- 2022
- Full Text
- View/download PDF